propranolol has been researched along with alprazolam in 35 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 12 (34.29) | 18.7374 |
1990's | 5 (14.29) | 18.2507 |
2000's | 11 (31.43) | 29.6817 |
2010's | 7 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
Abraham, MH; Acree, WE; Ibrahim, A | 1 |
Artursson, P; Bergström, CA; Draheim, R; Holmén, AG; Wassvik, CM | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
Artursson, P; Mateus, A; Matsson, P | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Friedman, MJ; Hauri, PJ; McHugo, GJ; Ravaris, CL | 1 |
Engel, JA; Söderpalm, B | 1 |
Baldwin, HA; File, SE | 1 |
Brown, R; Cabe, D; Crocker, B; Leonard, M; McDowell, D; McManus, M; Munjack, DJ; Palmer, R; Usigli, R; Zulueta, A | 1 |
Friedman, M; Hauri, PJ; Ravaris, CL | 1 |
Luchins, DJ; Meltzer, HY; Sommers, AA | 1 |
Ciancio, SG | 1 |
Blatt, M; Chernoff, RW; Mendels, J | 1 |
Rosenbaum, JF; Tesar, GE | 1 |
Doare, L; Puech, AJ; Simon, P; Thiebot, MH | 1 |
Patterson, WM; Shehi, M | 1 |
Greenblatt, DJ; Ochs, HR; Verburg-Ochs, B | 1 |
Stickler, GB; Van Winter, JT | 1 |
Abel, EL; Hannigan, JH | 1 |
Baltazar, PL; Brown, RA; Cabe, DD; McDowell, DE; Munjack, DJ | 1 |
Benschop, RJ; Jacobs, R; Raab, JR; Schedlowski, M; Schmidt, RE; Schürmeyer, TH; Sommer, B | 1 |
Luggen, AS | 1 |
Gironell, A | 1 |
Struble, LM | 1 |
3 review(s) available for propranolol and alprazolam
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Therapeutical strategies for essential tremor].
Topics: Adult; Aged; Alprazolam; Amines; Antipsychotic Agents; Botulinum Toxins, Type A; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Deep Brain Stimulation; Essential Tremor; Fructose; Gabapentin; gamma-Aminobutyric Acid; Head Movements; Humans; Middle Aged; Primidone; Propranolol; Severity of Illness Index; Thalamus; Topiramate; Tranquilizing Agents; Voice Disorders | 2007 |
Tremors: learning to stop the shakes.
Topics: Adrenergic beta-Antagonists; Alprazolam; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Learning; Propranolol; Self Efficacy; Theophylline; Tremor; Vasodilator Agents | 2010 |
6 trial(s) available for propranolol and alprazolam
Article | Year |
---|---|
A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Double-Blind Method; Female; Humans; Male; Middle Aged; Panic; Panic Disorder; Personality Assessment; Propranolol; Psychometrics | 1991 |
Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Clinical Trials as Topic; Double-Blind Method; Fear; Female; Humans; Male; Middle Aged; Panic; Phobic Disorders; Propranolol; Psychological Tests | 1989 |
Sleep in patients with spontaneous panic attacks.
Topics: Adolescent; Adult; Alprazolam; Cerebral Cortex; Clinical Trials as Topic; Double-Blind Method; Electroencephalography; Evoked Potentials; Fear; Female; Humans; Male; Middle Aged; Panic; Phobic Disorders; Propranolol; Reaction Time; Sleep Stages; Sleep Wake Disorders; Sleep, REM | 1989 |
The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
Topics: Alprazolam; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Dextroamphetamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Propranolol; Psychiatric Status Rating Scales; Psychotropic Drugs; Schizophrenia; Schizophrenic Psychology | 1986 |
Alprazolam as an adjunct to propranolol in anxious outpatients with stable angina pectoris.
Topics: Adult; Aged; Alprazolam; Angina Pectoris; Anxiety; Benzodiazepines; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Middle Aged; Propranolol; Sleep Stages | 1986 |
Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines.
Topics: Adrenergic beta-Antagonists; Adult; Alprazolam; Anti-Anxiety Agents; Cell Line; Humans; Hydrocortisone; Killer Cells, Natural; Male; Propranolol; Splenectomy; Stress, Psychological | 1996 |
26 other study(ies) available for propranolol and alprazolam
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Molecular characteristics for solid-state limited solubility.
Topics: Chemical Phenomena; Chemistry, Physical; Molecular Structure; Multivariate Analysis; Pharmaceutical Preparations; Regression Analysis; Solubility | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Alpha 1- and beta-adrenoceptor stimulation potentiate the anticonflict effect of a benzodiazepine.
Topics: Alprazolam; Animals; Conflict, Psychological; Dose-Response Relationship, Drug; Male; Prazosin; Propranolol; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Yohimbine | 1990 |
Caffeine-induced anxiogenesis: the role of adenosine, benzodiazepine and noradrenergic receptors.
Topics: 2-Chloroadenosine; Adenosine; Alprazolam; Anxiety; Caffeine; Chlordiazepoxide; Clonidine; Flumazenil; Motor Activity; Muscle Relaxants, Central; Norepinephrine; Propranolol; Receptors, Adrenergic; Receptors, GABA-A; Receptors, Purinergic; Social Behavior | 1989 |
More commonly prescribed medications.
Topics: Alprazolam; Atenolol; Dental Care; Drug Therapy; Furosemide; Humans; Ibuprofen; Propranolol | 1988 |
Successful use of clonazepam in patients with treatment-resistant panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clonazepam; Desipramine; Fear; Female; Humans; Imipramine; Male; Middle Aged; Panic; Phenelzine; Propranolol; Psychiatric Status Rating Scales | 1986 |
U 43,465F: a benzodiazepine with antidepressant activity? Interaction with Ro 15-1788 and d,1-propranolol.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents; Apomorphine; Benzodiazepines; Benzodiazepinones; Body Temperature; Drug Interactions; Flumazenil; Male; Mice; Propranolol | 1982 |
Treatment of panic attacks with alprazolam and propranolol.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Drug Synergism; Drug Therapy, Combination; Fear; Female; Humans; Male; Middle Aged; Panic; Propranolol | 1984 |
Propranolol interactions with diazepam, lorazepam, and alprazolam.
Topics: Adolescent; Adult; Alprazolam; Benzodiazepines; Biotransformation; Chromatography, High Pressure Liquid; Diazepam; Drug Interactions; Female; Humans; Injections, Intravenous; Kinetics; Lorazepam; Male; Nordazepam; Propranolol | 1984 |
Panic attack syndrome.
Topics: Alprazolam; Antidepressive Agents; Anxiety Disorders; Benzodiazepines; Child; Fear; Humans; Hyperventilation; Imipramine; Male; Monoamine Oxidase Inhibitors; Panic; Phenelzine; Phobic Disorders; Propranolol; Syndrome | 1984 |
Panic attacks: a debilitating disorder for millions.
Topics: Alprazolam; Benzodiazepines; Fear; Female; Humans; Male; Panic; Propranolol | 1983 |
The immobility response in the forced swim test: paradoxical effect of imipramine.
Topics: Alprazolam; Animals; Behavior, Animal; Imipramine; Male; Motor Activity; Propranolol; Rats; Rats, Inbred F344 | 1994 |
A naturalistic follow-up of panic patients after short-term pharmacologic treatment.
Topics: Adult; Alprazolam; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Panic Disorder; Personality Inventory; Propranolol | 1993 |
Essential tremor in the older adult: coping with primary symptoms.
Topics: Acetates; Adaptation, Psychological; Adrenergic beta-Antagonists; Aged; Alprazolam; Amines; Anticonvulsants; Antiparkinson Agents; Botulinum Toxins, Type A; Cyclohexanecarboxylic Acids; Essential Tremor; GABA Modulators; Gabapentin; gamma-Aminobutyric Acid; Humans; Neuromuscular Agents; Primidone; Propranolol; Severity of Illness Index | 2004 |